AdipoGen Life Sciences Manumycin A exosome biogenesis inhibitor

Exosomes are small vesicles (~30 to 100 nm in diameter) that are released by cells into the extracellular space. Some recent studies have found exosomes to be a potential diagnostic marker for cancer and other diseases, while others have investigated the use of exosomes to deliver therapeutic molecules to specific cells or tissues.

Manumycin A, a natural antibiotic, was identified as an inhibitor of exosome biogenesis and secretion. Manumycin A is a selective inhibitor of FTase. By inhibiting the farnesylation of RAS, Manumycin A suppresses RAS/RAF/ERK1/2 signalling and reduces exosome generation. Targeting exosome biogenesis might be crucial for RAS signalling inhibitors to exert their anticancer effects.

AdipoGen Life Sciences’ Manumycin A compound has been found to have a variety of biological activities, including antimicrobial activity against a wide range of bacteria, including gram-positive and gram-negative species. It is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant bacteria.

The compound also has antitumor activity against a variety of cancer cell lines, including breast, ovarian and lung cancer. It works by inducing apoptosis (programmed cell death) in cancer cells and inhibiting angiogenesis in tumours.

It also offers anti-inflammatory activity, by inhibiting the production of pro-inflammatory molecules such as TNF-α and IL-6; exosome inhibitory activity, inhibiting the formation and release of exosomes; and immunomodulatory activity, modulating the immune system by upregulating the production of certain immune cells and cytokines.